Patient treatment complete in phase 2b blepharitis trial
The final patient has completed the treatment stage of a phase 2b clinical trial investigating NCX 4251 for blepharitis, according to a press release from Nicox.
The Mississippi trial, which is investigating NCX 4251 0.1% (fluticasone propionate nanocrystals ophthalmic suspension), recruited more than 200 patients. The primary outcome measures include the proportion of patients on NCX 4251 vs. placebo who achieve a complete cure in eyelid redness, eyelid debris and eyelid discomfort at day 15.
“The Mississippi trial includes a number of clinical endpoints related to signs and symptoms of blepharitis and dry eye disease,” José Boyer, PhD, interim head of research and development at Nicox, said in the release. “We will therefore generate a significant amount of data which will be used to guide the future development of NCX 4251.”
Nicox plans to release topline data in September, the release said.